{"id":"placebo-of-ad-227b","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a placebo of AD-227B, this formulation contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active drug to maintain blinding in phase 3 studies. Any observed effects are attributable to placebo response rather than direct drug action.","oneSentence":"This is a placebo control formulation with no active pharmacological mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:06.314Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06441630","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B","status":"RECRUITING","sponsor":"Addpharma Inc.","startDate":"2024-07-31","conditions":"Essential Hypertension","enrollment":251}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of AD-227B","genericName":"Placebo of AD-227B","companyName":"Addpharma Inc.","companyId":"addpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}